PRESS RELEASE: SCHWARZ PHARMA Announces FDA Approval of Parcopa(TM) Orally
Dissolving Tablets for Parkinson's Disease
Monday August 30, 8:10 am ET

MILWAUKEE, Aug. 30 /PRNewswire/ -- SCHWARZ PHARMA, INC., announced today that it
has received approval from the U.S. Food and Drug Administration (FDA) to market
Parcopa(TM) (carbidopa-levodopa orally disintegrating tablets), a unique formulation of
carbidopa-levodopa that dissolves rapidly on the tongue. Parcopa, which will be available in
pharmacies September 27, 2004, is designed to provide patients suffering from Parkinson's
disease improved access to their medication.
(Photo: http://www.newscom.com/cgi-bin/prnh/20040830/NYM019 )

Parkinson's disease patients experience symptoms such as morning rigidity or "off periods" --
episodes of decreased movement or complete immobility during the day -- that can make
dosing problematic. Unlike conventional carbidopa-levodopa tablets, Parcopa dissolves on the
tongue using RapiTab(TM) technology to deliver medicine without the need for water, providing
patients with a convenient means to take their medication.

"Parkinson's disease presents patients with a host of challenges that affect almost every
aspect of their daily lives, including their ability to take medications that are necessary," said
Ron Stratton, Ph.D., president and COO of SCHWARZ PHARMA, INC. "Parcopa was
developed to offer a simpler and more convenient way for patients to access critical levodopa
replacement therapy. For instance, because Parcopa does not require water, patients can
easily take it upon waking to help get morning routines moving, resulting in an easier start to
the day. They may also attain a greater sense of control over daily activities and reduce
concern about dosing to treat 'off periods' by having Parcopa readily accessible at all times."

Parcopa is available in the same strengths and has the same dosage schedule as
conventional Sinemet® (carbidopa-levodopa) Tablets. The most common side effects include
involuntary movements and nausea. Each 10 mg/100 mg tablet and each 25 mg/100 mg tablet
contain phenylalanine 3.4 mg. Each 25 mg/250 mg tablet contains phenylalanine 8.4 mg. For
more information about Parcopa, talk to your healthcare provider or visit
http://www.Parcopa.com

About RapiTab(TM) Technology

SCHWARZ PHARMA's RapiTab(TM) Technology formulates medicines into orally
disintegrating tablets that dissolve rapidly on the tongue. They can be swallowed with or
without water and have pleasant tasting flavors such as citrus or mint. RapiTab tablets are
convenient and easy for patients to administer, especially when water is not readily available or
patients face certain obstacles to dosing. SCHWARZ PHARMA's RapiTab Technology is
based on the proprietary DuraSolv technology developed by and licensed from CIMA LABS
INC.®

RapiTab Technology has distinct advantages over freeze-dry technology. RapiTab Tablets are
pleasant tasting, have good mouth feel and are easily soluble both in water and saliva. It can
be used with a wide range of active ingredients and strengths. Unlike many other forms of fast-
dissolve tablets, RapiTab tablets are durable and can be packaged in both blister packs and
conventional bottles.

SCHWARZ PHARMA will use patented RapiTab Technology to develop a family of prescription
pharmaceutical products for use in primary care, gastroenterology and neurology.

For more information on RapiTab Technology, please visit our web site at
http://www.RapiTabtech.com

The SCHWARZ PHARMA CNS Pipeline

SCHWARZ PHARMA is highly committed to the treatment of neurological disorders and has a
robust pipeline including rotigotine CDS, a new dopamine agonist for transdermal treatment of
Parkinson's disease. The Company recently reported successful completion of Phase III trials
and plans to file for regulatory approval in Q3 2004. The Company is also investigating the use
of rotigotine CDS for treatment of Restless Legs Syndrome (RLS), an unpleasant hyperkinesia
of the legs that occurs primarily at night.

Harkoseride, a novel agent being investigated for both the treatment of epilepsy and
neuropathic pain, is currently in Phase III trials.

About SCHWARZ PHARMA

SCHWARZ PHARMA, INC., based in Milwaukee, WI, is a pharmaceutical company with
proven expertise in the areas of cardiology, gastroenterology, urology and neurology.
SCHWARZ PHARMA, INC., is an affiliate of SCHWARZ PHARMA AG (headquartered in
Monheim, Germany). The SCHWARZ PHARMA Group develops and markets innovative drugs
for unmet medical needs with a focus on the therapeutic areas of neurology, urology as well as
cardiovascular and gastrointestinal diseases. The Company is investing in research and
development projects targeting diseases such as Parkinson's disease, Restless Legs
Syndrome, epilepsy, neuropathic pain, overactive bladder syndrome/incontinence and benign
prostatic hyperplasia. SCHWARZ PHARMA has a strong multinational presence that includes
affiliates in Europe, the U.S. and Asia. Shares of SCHWARZ PHARMA AG are traded on the
Frankfurt and Dusseldorf stock exchanges.

Contact at SCHWARZ PHARMA AG / Investor Relations: Antje Witte; Phone: +49 2173 48
1866; email: [log in to unmask]

For more information about SCHWARZ PHARMA, visit http://www.schwarzusa.com or
http://www.schwarzpharma.com

Sinemet® (carbidopa-levodopa) is a registered trademark of Merck & Co., Inc.

This press release contains forward-looking statements based on current plans, estimates and
beliefs of the management of SCHWARZ PHARMA AG. These forward-looking statements are
subject to various risks and uncertainties that may cause actual results to differ materially from
those expressed or implied by such forward-looking statements. Risks and uncertainties that
could cause a material difference in future results include changes in business, economic and
competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in
litigation or investigative proceedings and the availability of financing. The Company does not
undertake any responsibility to update the forward-looking statements contained in this press
release.

Source: SCHWARZ PHARMA, INC.

SOURCE: Yahoo News (press release)
http://biz.yahoo.com/prnews/040830/nym019_1.html

* * *

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn